Skip to main content
Premium Trial:

Request an Annual Quote

Bruker's Q1 Revenues Up 21 Percent

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Bruker today reported first-quarter 2010 revenue growth of 21 percent, with strong sales from both its Bruker Scientific Instruments (BSI) segment and Bruker Energy & Supercon Technologies (BEST) segment.

The Billerica, Mass.-based firm generated total revenues of $277.7 million for the three months ended March 31, compared to $230.5 million for the first quarter of 2009. Its products revenues were $244 million versus $202.2 million for Q1 2009, while its service revenues were $31.5 million versus $26.9 million. Its "other" revenues were $2.2 million compared to $1.4 million for Q1 2009.

Bruker said that excluding the effects of foreign currency, its Q1 revenues rose around 12 percent.

By segment, BSI brought in $260.3 million compared to $223.6 million for the prior year's first quarter, while BEST's revenues more than doubled to $20.7 million from $8.1 million.

Bruker beat analysts' consensus estimate for revenues of $256.8 million.

"All four operating divisions in our BSI segment delivered double-digit growth year-over-year, and our BEST segment had triple-digit growth for the second quarter in a row," Bruker President and CEO Frank Laukien, said in a statement. "The industrial and applied markets continued to improve gradually during the first quarter, and overall we recorded healthy new order bookings, including more than $10 million in additional US stimulus orders, all of which contributed to strong backlog at the end of the first quarter."

The firm's profit for the quarter nearly doubled to $16.1 million, or $.10 per share, from $8.4 million, or $.05 per share. It beat Wall Street's expectations of $.08.

Its R&D expenses increased 13 percent to $32.8 million from $29.1 million, while its SG&A spending increased 12 percent to $66.1 million from $58.9 million.

Bruker finished the quarter with $206.6 million in cash, cash equivalents, and restricted cash.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.